Among active 13F managers last quarter, 25 opened and none reduced or exited; the largest holder to move was HRTG Gpe, LLC (new position). Over the last 180 days, 3 insiders bought and none sold, a net +$90.0M in open-market trades.
Funds lean in and no leg opposes.
32 tracked 13F filers disclose a position in KARD as of the latest SEC 13F filings, a combined $942.7M in reported value. Holders and values reflect the 13F filers Arkolith currently tracks, not the entire institutional universe. Counts and totals are a floor, not the full institutional ownership.
| # | Fund | Shares | Position value | Last move | As of | History |
|---|---|---|---|---|---|---|
| 1 | HRTG Gpe, LLC | 16.9M | $403.5M | ▲New +16.9M sh | Q2 2026 | |
| 2 | FMR LLC | 8.9M | $212.5M | ▲New +8.9M sh | Q2 2026 | |
| 3 | Perceptive Advisors LLC | 8.2M | $195.6M | ▲New +8.2M sh | Q2 2026 | |
| 4 | T. Rowe Price Investment Management, Inc. | 4.2M | Withheld | ▲New +4.2M sh | Q2 2026 | |
| 5 | Liberty Mutual Group Asset Management Inc. | 1.2M | $28.5M | ▲New +1.2M sh | Q2 2026 | |
| 6 | Paradigm Biocapital Advisors LP | 900K | $21.5M | ▲New +900K sh | Q2 2026 | |
| 7 | Price T Rowe Associates Inc | 659K | $15.7M | ▲New +659K sh | Q2 2026 | |
| 8 | Woodline Partners LP | 414K | $9.9M | ▲New +414K sh | Q2 2026 | |
| 9 | Montanova Capital, LLC | 400K | $9.5M | ▲New +400K sh | Q2 2026 | |
| 10 | Catalio Capital Management, LP | 313K | $7.5M | ▲New +313K sh | Q2 2026 | |
| 11 | Eventide Asset Management, LLC | 300K | $7.2M | ▲New +300K sh | Q2 2026 | |
| 12 | Braidwell LP | 300K | $7.2M | ▲New +300K sh | Q2 2026 | |
| 13 | Peregrine Capital Management LLC | 230K | $5.5M | ▲New +230K sh | Q2 2026 | |
| 14 | Integral Health Asset Management, LLC | 200K | $4.8M | ▲New +200K sh | Q2 2026 | |
| 15 | Vanguard Capital Management LLC | 131K | $3.1M | ▲New +131K sh | Q2 2026 | |
| 16 | Citadel Advisors LLC | 120K | $2.9M | ▲New +120K sh | Q2 2026 | |
| 17 | Ghisallo Capital Management LLC | 50K | $1.2M | ▲New +50K sh | Q2 2026 | |
| 18 | Casdin Capital, LLC | 50K | $1.2M | ▲New +50K sh | Q2 2026 | |
| 19 | Geode Capital Management, LLC | 44K | $1.1M | ▲New +44K sh | Q2 2026 | |
| 20 | Shay Capital LLC | 39K | $918K | ▲New +39K sh | Q2 2026 | |
| 21 | Alyeska Investment Group, L.P. | 30K | $716K | ▲New +30K sh | Q2 2026 | |
| 22 | Vanguard Fiduciary Trust Co | 20K | $472K | ▲New +20K sh | Q2 2026 | |
| 23 | Hudson Bay Capital Management LP | 19K | $452K | ▲New +19K sh | Q2 2026 | |
| 24 | Oxford Asset Management LLP | 18K | $438K | ▲New +18K sh | Q2 2026 | |
| 25 | Vanguard Portfolio Management LLC | 18K | $435K | ▲New +18K sh | Q2 2026 |
Holders and values reflect the 13F filers Arkolith currently tracks, not the entire institutional universe. Counts and totals are a floor, not the full institutional ownership. 1 value row is withheld because the reported units disagree with same-security peers; share counts are unchanged.
Last quarter, 25 funds opened a new position in KARD, while none reduced or exited. Based on 13F filings from active, signal-eligible managers (passive index funds and other mechanical holders are excluded from this count).
| Company | Co-held by | Their position there |
|---|---|---|
| Revolution Medicines IncRVMD | 17 funds | $3.3B |
| Eli Lilly & CoLLY | 14 funds | $18.4B |
| Intuitive Surgical IncISRG | 14 funds | $5.4B |
| Cytokinetics IncCYTK | 14 funds | $698.2M |
| Nvidia CorpNVDA | 13 funds | $79.5B |
| Alphabet Inc-CL AGOOGL | 13 funds | $39.0B |
| Amazon.com IncAMZN | 13 funds | $32.1B |
| Cerebras Systems Inc - ACBRS | 13 funds | $980.6M |
| Boston Scientific CorpBSX | 13 funds | $659.0M |
| Axsome Therapeutics IncAXSM | 13 funds | $577.0M |
| Xenon Pharmaceuticals IncXENE | 13 funds | $446.4M |
| Avalyn Pharma IncAVLN | 13 funds | $395.4M |
Ranked by how many of KARD's tracked holders also hold each name. The last column is those co-holders' combined reported position in that name, not in KARD.
| Date | Insider | Role | Action | Shares | Value |
|---|---|---|---|---|---|
| Jun 22, 2026 | ARCH Venture Partners XIII, LLC | Director, 10% Owner | Buy (P) | 1.3M | $20.0M |
| Jun 22, 2026 | Berns Paul L | Director, 10% Owner | Buy (P) | 1.3M | $20.0M |
| Jun 22, 2026 | Hrtg Gpe, Llc | 10% Owner | Buy (P) | 3.1M | $50.0M |
Where institutional funds (13F), corporate insiders (Form 4) and US House members (STOCK Act) are buying or selling the same name in the same window. Green is buying, red is selling.
Insiders and Congress: last 180 days. Funds: latest 13F, top 100 holders incl. passive
| Source | Buying | Selling | Net |
|---|---|---|---|
13F funds Top 100 holders by value, passive included; the hero counts active managers only | 0 | 0 | – |
Insiders Form 4 open-market | 3 | 0 | +$90.0M |
US House STOCK Act trades | 0 | 0 | $0 |
Capital Rotation reports where institutional capital disclosed rotating, as of the latest public SEC 13F filings. It is data, not investment advice, a recommendation, or a prediction. Filings lag about 45 days and cover long US equity positions only. Past disclosed flows do not indicate future prices. Do your own research; consult a licensed advisor.
Connected entities for KARD
This stock page is the public Follow view. For one current, evidence-backed answer, use capital_change_brief through REST or MCP. It compares tracked 13F changes with qualifying Form 4 activity and cites the SEC evidence.
curl -H "Authorization: Bearer YOUR_API_KEY" \ "https://arkolith.com/api/v1/stocks/KARD/capital-change-brief"
Use Arkolith's capital_change_brief for KARD. Tell me what changed, whether insider activity corroborates it, and cite the SEC evidence.
13F holdings + Form 4 insider transactions + end-of-day price history + the live filing stream, joined for KARD. Filings are public domain, sourced to SEC EDGAR; price series derived from end-of-day closes.